Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Arrowhead Research Corporation and Axolabs GmbH Enter into Strategic Alliance and Master Services Agreement for RNAi Therapeutics

Abstract:
Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement.

Arrowhead Research Corporation and Axolabs GmbH Enter into Strategic Alliance and Master Services Agreement for RNAi Therapeutics

Pasadena, CA | Posted on March 5th, 2012

Under the terms of the agreement, Axolabs, founded by the principals of former Roche Center of Excellence for RNAi Therapeutics in Kulmbach, Germany, will provide Arrowhead and its partners first-in-class oligonucleotide optimization, synthesis, and analytics. These services include bioinformatics for siRNA design; lead identification, optimization and characterization; as well as siRNA synthesis and CMC-related activities.

"With multiple candidates in the clinic addressing a wide range of indications, data demonstrating the power of RNAi as a therapeutic modality are rapidly accumulating," said Dr. Christopher Anzalone, Arrowhead's CEO. "Axolabs' scientists are pioneers in the field. Having access to their expertise in preclinical development complements Arrowhead's capabilities well and provides us with yet another tool for preclinical and clinical collaborations in the field. Now, with the company's already established intellectual property position and array of proprietary delivery technologies including Dynamic PolyConjugates™ and RONDEL™, Arrowhead is uniquely positioned to build its own pipeline of RNAi therapeutics and provide partners entry to this promising area in a rapid and cost effective manner."

"This agreement continues the execution of Axolabs' strategy to become the preeminent custom research organization in the oligonucleotide therapeutics field," added Dr. Roland Kreutzer, Managing Director of Axolabs GmbH. "We know the colleagues at Arrowhead very well. We are happy to support them in establishing a leading role in the area of RNAi therapeutics and excited to be chosen as their preclinical service provider."

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage nanomedicine company developing innovative therapies at the interface of biology and nanoengineering. Arrowhead's world-class capabilities and intellectual property covering nucleic acid delivery, siRNA chemistry, and tissue targeting allow it to design and develop therapeutic agents for a wide range of diseases. The company's lead products include CALAA-01, an oncology drug candidate based on the gene silencing RNA interference (RNAi) mechanism, and Adipotide, an anti-obesity peptide that targets and kills the blood vessels that feed white adipose tissue. Arrowhead is leveraging its proprietary Dynamic PolyConjugate (DPC), Liposomal Nanoparticle (LNP), and RONDEL delivery platforms to support its own pipeline of preclinical and clinical candidates and to secure external partnerships and collaborations with biotech and pharmaceutical companies. For more information, please visit www.arrowheadresearch.com.

About Axolabs



Axolabs is a custom research organization providing high-end preclinical solutions and consultancy in the field of oligonucleotide therapeutics. Axolabs' services comprise oligonucleotide synthesis as well as related analytics, bioanalytics and pharmacology. Built on the foundations of the former Roche Center of Excellence for RNA Therapeutics in Kulmbach, Germany, the company has long-term experience in the development of oligonucleotide therapeutics. For more information, please visit www.axolabs.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Investor Relations Contact:
The Trout Group, LLC
Michael Levitan
646-378-2920


Axolabs GmbH
+49 9221 827 620

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Study details laser pulse effects on behavior of electrons November 28th, 2014

Single-atom gold catalysts may offer path to low-cost production of fuel and chemicals November 28th, 2014

Production of Anticancer Drug from Nanofibers in Iran November 28th, 2014

The mysterious 'action at a distance' between liquid containers November 26th, 2014

Nanomedicine

Production of Anticancer Drug from Nanofibers in Iran November 28th, 2014

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

ASU, IBM move ultrafast, low-cost DNA sequencing technology a step closer to reality November 24th, 2014

An Inside Job: UC-Designed Nanoparticles Infiltrate, Kill Cancer Cells From Within November 24th, 2014

Announcements

Study details laser pulse effects on behavior of electrons November 28th, 2014

Single-atom gold catalysts may offer path to low-cost production of fuel and chemicals November 28th, 2014

Production of Anticancer Drug from Nanofibers in Iran November 28th, 2014

The mysterious 'action at a distance' between liquid containers November 26th, 2014

Alliances/Partnerships/Distributorships

SEMATECH to Showcase Innovation and Advances in Manufacturing at SEMICON Japan 2014: SEMATECH experts will share the latest techniques, emerging trends and best practices in advanced manufacturing strategies and methodologies November 26th, 2014

New research project supports internationalisation in nano-research: Launch of new “Baltic Sea Network” November 22nd, 2014

UO-industry collaboration points to improved nanomaterials: University of Oregon microscope puts spotlight on the surface structure of quantum dots for designing new solar devices November 20th, 2014

A novel method for identifying the body’s ‘noisiest’ networks November 19th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE